Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now?

Liquidia (LQDA) and Insmed (INSM) are compared as commercial-stage biopharmaceutical companies focused on pulmonary hypertension treatments. LQDA shows impressive commercial momentum with Yutrepia generating $170.4M in Q2 sales and achieving four consecutive profitable quarters, but faces heavy reliance on a single product. INSM offers a more diversified portfolio with Brinsupri's strong launch ($1.25-$1.40B 2026 guidance) and established Arikayce revenue, plus a broader pipeline. While LQDA has outperformed INSM significantly this year (106.9% vs -28.5%), analysts recommend INSM as the more compelling long-term choice due to its diversified revenue base and sustainable growth story.